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ABSTRACT: The role of the adenosine A3 receptor continues to baffle, and, de-
spite an increasing number of studies, the currently available data add to, rath-
er than alleviate, the existing confusion. The reported effects of adenosine A3
receptor stimulation appear to depend on the pattern of drug administration
(acute vs. chronic), dose, and type of the target tissue. Thus, while acute expo-
sure to A3 receptor agonists protects against myocardial ischemia, it is severely
damaging when these agents are given shortly prior to cerebral ischemia. Mast
cells degranulate when their A3 receptors are stimulated. Degranulation of
neutrophils is, on the other hand, impaired. While reduced production of reac-
tive nitrogen species has been reported following activation of A3 receptors in
collagen-induced arthritis, the process appears to be enhanced in cerebral is-
chemia. Indeed, immunocytochemical studies indicate that both pre- and pos-
tischemic treatment with A3 receptor antagonist dramatically reduces nitric
oxide synthase in the affected hippocampus. Even more surprisingly, low doses
of A3 receptor agonists seem to enhance astrocyte proliferation, while high dos-
es induce their apoptosis. This review concentrates on the studies of cerebral
A3 receptors and, based on the available evidence, discusses the possibility of
adenosine A3 receptor serving as an integral element of the endogenous cere-
bral neuroprotective complex consisting of adenosine and its receptors.
THE NATURE OF THE ADENOSINE A3 RECEPTOR
In the very beginning of the present decade, the family of adenosine receptors
(A1, A2A, and A2B) increased by the addition of another distinct type—the A3 recep-
tor. Cloning of the cDNA from the rat testis library revealed approximately 40%
identity with A1 and A2A types.
1 Further cloning studies2–4 revealed intriguing dif-
ferences in the degree of homologies among different species, indicating a possibil-
ity that A3 receptors may, in fact, exist as a range of subtypes.
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The A3 receptor is a G-protein-coupled entity and, like all other known receptors
of this type, consists of a long polypeptide chain with seven α-helices residing with-
in the cellular membrane ending in an extracellular N- and an intracellular C-termi-
nus.6 The region between the central and the extracellular region of V–VII helices
appears to constitute the active site of the receptor.6 Signal transduction at the A3 re-
ceptor is mediated by Gi/Go proteins,
7,8 and the receptor appears to regulate their ex-
pression. The latter process is, however, somewhat heterogenous, and the responses
of different subunits to the receptor’s prolonged exposure to an agonist differ.7 Long-
lasting stimulation of A3 receptors in vitro also results in their functional
desensitization9 and a noticeable reduction of high-affinity binding sites.7 A detailed
discussion can be found in the reviews by Palmer and Stiles8 and Olah and Stiles.10
In the context of the present paper, the finding that A3 receptors desensitize rapidly
may provide at least partial explanation for rather striking outcome differences ob-
served following acute or chronic exposure to A3 receptor agonists in vivo (see
below).
Adenyl cyclase and phospholipase C serve as the second messenger systems of
the A3 receptor. Its stimulation results in depression of cyclic adenosine-5′,3′-mono-
phosphate (cAMP) synthesis2,3 or activation of phospholipase C11 and subsequent
stimulation of inositol-1,4,5-triphosphate synthesis.12 Although it is unlikely that
both second messengers are triggered into action at the same time, there are present-
ly no studies analyzing these processes in detail. However, recent observations on
the dependence of astrocytic response on the concentration of the stimulating A3
agonist13 (see below) indicate the possibility that the intensity and/or duration of re-
ceptor activation may have a possibly preferential impact on the selection of the sec-
ond messenger system.
Probably the most striking aspect of A3 receptor pharmacology is its very low af-
finity for adenosine. Although more recent studies reduced the original estimates of
Ki from 30 µM2 to 1 µM,5 the value is still approximately two orders of the magni-
tude higher than that characterizing either A1 or A2 receptors (10 and 30 nM, respec-
tively). The low affinity of A3 receptors for adenosine poses one of many difficulties
in envisaging the biological role of the receptor since, under the normal conditions,
the extracellular concentration of adenosine in the brain does not exceed 300 nM (for
review, see Ref. 14). However, none of the currently available methods of measuring
adenosine concentration in the normal brain offers any indication of its value in the
“operational” areas of neurons, i.e., perisynaptic space. Hence, intense synaptic ac-
tivity, even under the normal conditions, may elevate local adenosine concentration
to the level that is sufficient for A3 receptor activation. Recent physiological studies
of Dunwiddie et al.15 indicate such a possibility. While interspecies differences in
the affinity of A3 receptors for antagonists are also striking, it is more likely that they
mirror differences of receptor structure rather than function as such.16 Much less
pronounced, the variability in agonist affinity has been demonstrated as well.16
The progress in understanding of the 3-dimensional structure of A3 receptors that
derived from introduction of new techniques17 is paralleled by a continuously in-
creasing availability of selective A3 receptor agonists and antagonists.
18–20 Regret-
tably, the development of these agents is not matched by the corresponding effort to
synthesize equally selective radio-labeled ligands. Hence, our knowledge of A3 re-
ceptor distribution is comparatively meagre, although considerable variation both in
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its distribution and density among several nonhuman mammalian species has been
reported.5,16 The exact cellular location of A3 receptors is still unknown as much in
the brain as elsewhere.
THE ACTIONS OF ADENOSINE A3 RECEPTOR
Nonneural Tissues
Most of the hitherto known effects elicited by the stimulation of A3 receptors
have been reviewed in the volume of The Annals of the New York Academy of Sci-
ences devoted to the preceding Conference on Neuroprotective Agents held at Lake
Como, Italy in 1996.14 Since that time, experimental work concentrated predomi-
nantly (and unsurprisingly in view of the clinical uses of adenosine) on cardiovascu-
lar involvement of A3 receptors shown to participate in hypotensive and
vasoconstrictive responses,21–24 and in cardioprotection both in myocytes25–27 and
in perfused rabbit hearts.28 While there are indications that A3 receptors may also be
involved in ischemic preconditioning (IP) of the heart, the exact nature of their con-
tribution to the phenomenon appears to need further clarification. Thus, while show-
ing that the agonists of both A1 and A3 receptors mimic cardiac IP, Hill et al.
29 also
indicated that A1 rather than A3 receptors are the principal source of the adenosine-
mediated component of preconditioning. Other authors30 concluded, however, that
both receptors seem to play a role, while others described a complex interaction of
adenosine A1/A3 and bradykinin B2 receptors.
31
Several recent studies focused their attention on the antiinflammatory effect of
adenosine A3 receptor agonists, e.g., prevention of neutrophil degranulation,
24 atten-
uation of inflammatory mediator,33 and chemo- and cytokine release.33–35 More-
over, since stimulation of A3 receptors markedly decreases eosinophil
chemotaxis,35,36 it has been suggested that A3 receptor agonists may be potentially
useful in treatment of the pulmonary (asthma) and rheumatoid disorders.32,33
Nervous System
Astrocytes and hippocampal neurons have been the primary target of in vitro
studies of the effects elicited by A3 receptors. Fleming and Mogul
37 showed that ex-
posure to the nonselective A3 receptor agonist N
6-2-(4-aminophenyl)ethyl-adenos-
ine (APNEA) potentiated high threshold Ca2+ current. The potentiating effect was
sustained in the presence of A1 and A2 receptor antagonists and of protein kinase C
(PKC) peptide inhibitor. The inhibitor of protein kinase A, on the other hand,
blocked the potentiation. Since activation of A3 receptors also results in the depres-
sion of adenylyl cyclase,2,3 the authors concluded that PKA is negatively coupled to
the Ca2+ current. The latter finding may have a significance in explaining at least
some of the consequences following preischemic exposure of A3 to selective ago-
nists (see below; also the review of Domanska-Janik38 on the importance of various
protein kinases in the generation of ischemic damage). Of similar importance are the
studies of Dunwiddie et al.15 showing that stimulation of A3 receptors with a selec-
tive agonist 2-chloro-N6-(iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-
MECA) antagonizes adenosine A1 receptor-mediated inhibition of excitatory neu-
96 ANNALS NEW YORK ACADEMY OF SCIENCES
rotransmission. Similar functional disinhibition results from A3 receptor inhibitory
influence on the function of presynaptic group III metabotropic glutamate receptors
(metGluRs)39 that are responsible for the reduction of glutamatergic neurotransmis-
sion at a wide variety of synapses.40
A series of papers by Abbracchio et al.13,41 and Yao et al.42 indicated that the re-
sponse of astrocytes to A3 receptor stimulation is clearly dependent on its intensity,
confirming theoretical arguments of von Lubitz et al.43 based on their studies of
acute and chronic administration of A3 receptor agonists. Thus, Abbracchio et
al.13,41 reported that exposure of human astrocytoma ADF cells to nanomolar con-
centration of the selective A3 receptor agonist Cl-IB-MECA results in increased
ramification of astrocytes accompanied by reorganization of cytoskeleton, accompa-
nied by Bcl-XL protein expression within the newly appeared astrocyte protrusions.
Higher (micromolar) concentrations of the drug resulted in apoptosis.41 Similar,
concentration-dependent results were also obtained in the studies of human leuke-
mia (HL-6) and lymphoma (U-937) cells.42 Finally, a very high concentration of Cl-
IB-MECA (>10 µM) is required to induce necrosis of cerebellar granule cells in cul-
ture.44 However, when the cells were exposed to 1 µM Cl-IB-MECA in the presence
of nontoxic glutamate concentration (50 µM), the necrosis was very rapid and virtu-
ally complete. Glutamate alone had no effect.
The data on the effect of adenosine A3 receptor stimulation obtained in isolated
cell systems may explain, at least in part, the outcome of in vivo acute exposure to
A3 agonist IB-MECA prior to global and focal cerebral ischemia
43 (see also this con-
ference). Significant delay in the normalization of the postischemic cortical blood
flow was the most immediate sign of the effect of the drug. Postischemic mortality
FIGURE 1. Acute administration of IB-MECA (100 µg/kg) 20 min prior to (PRE) or
20 min after (POST) initiation of permanent middle cerebral artery occlusion (MCAO) in
mice. Following removal, brain slices were stained with the 2,3,5-triphenyltetrazolium chlo-
ride monohydrate (TTC) method. Preischemic administration results in a larger infarct (ap-
proximately 40% increase compared to control animals (CONT), p >0.01, n = 15/group).
Compared to saline injected controls, administration of the drug after initiation of MCAO
shrunk the infarcted volume by approximately 20% (p >0.05, n = 15/group). 
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was substantially elevated, especially during the initial 3 days of postischemic recov-
ery, while neuronal damage (cortex, hippocampus, striatum) was intensified in the
surviving drug-treated animals at 7 days postischemia.14,43 These results are similar
to those obtained in the model of permanent middle cerebral artery occlusion in
mice, where the initial mortality among IB-MECA-treated (100 µg/kg) mice in-
creased by almost 30% (von Lubitz et al., this conference, and in preparation). In-
crease in the infarct size was also very significant (p >0.01, FIG. 1). Moreover, acute
preischemic treatment with IB-MECA elevated the presence of nitric oxide synthase
(NOS) and accelerated deterioration of cytoskeletal protein MAP-2 as shown using
quantitative and semiquantitative immunocytochemical methods.14,45 Chronic treat-
ment with daily IB-MECA doses as low as 5 µg/kg (daily for 60 days) had, on the
other hand, a diametrically opposite effect, i.e., improved postischemic blood flow,
reduced mortality, and a significantly better neuropathological and neurological
(e.g., improved postischemic memory and learning ability14) outcome. Finally, im-
munocytochemical expression of NOS was fully suppressed, and there was an excel-
lent preservation of MAP 2, accompanied by a striking increase in the density of
glial fibrillary acidic protein (GFAP, i.e., activated) astrocytes.45 Importantly, acute
preischemic treatment with the selective adenosine A3 receptor MRS 1191 repro-
duced the effects of chronic exposure to IB-MECA, indicating that the observed phe-
nomena were indeed A3 receptor-induced (Ref. 46, and in preparation).
It is unclear what mechanism is directly responsible for the in vivo effects of A3
receptor activation. As indicated in the preceding section, stimulation of A3 recep-
tors elicits a broad range of effects. Some of these, e.g., degranulation of mast cells
and vasoconstriction (which may be the mechanism behind retarded normalization
of the postischemic blood flow), attenuation of the inhibitory effects of A1 and
IIImetGLU receptors on glutamatergic neurotransmission, activation of NOS, or lib-
eration of intracellular Ca2+ stores and facilitation of extracellular Ca2+ influx47 are
highly damaging in the context of cerebral ischemia and the subsequent recovery.
Others, such as depression of eosinophil chemotaxis, reduction of neutrophil recruit-
ment, or inhibition of tumor necrosis factor-α (TNF-α) and macrophage inflamma-
tory protein (MIP)1-α release are quite beneficial, since studies have shown that
reduction of inflammatory phenomena results in improvement of postischemic out-
come in the brain.48–50 Astrocyte activation appears to be equally recovery-enhanc-
ing.51,52 One is thus presented with a complex mix of A3 receptor-induced effects,
some of which clearly promote, while others retard, the demise of ischemia-injured
neurons, and make the interpretation of A3 receptor involvement in brain pathology
a seemingly hopeless task. Yet, the studies that have emerged recently offer a number
of alluring clues which, taken together, indicate that adenosine A3 receptor may be
a very important constituent of a very efficient endogenous system defending brain
against injury.
ADENOSINE A3 RECEPTOR AND BRAIN INJURY:
A SPECULATION ON FACTS
All known, and often contradictory, aspects of adenosine A3 receptor-mediated
actions notwithstanding, two facts are strikingly prominent: their very wide interspe-
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cies distribution,16 and their very low affinity for adenosine.5 In the evolutionary
sense, its retention across the spectrum of several species, and its development into
a functionally identical entity of a significantly varying molecular structure indicate
that A3 receptor must have an important survival value. On the other hand, the very
low affinity of A3 receptor for its endogenous agonist, adenosine, and a very low ex-
tracellular concentration of the latter under normal conditions,53 also indicate that
the receptor is, most likely, dormant under most but the most extreme conditions.
Conditions such as encountered during ischemia, traumatic brain injury, or seizures,
where the brain is exposed to extreme metabolic stress, where the bulk of adenosine
released into the extracellular space originates from a furious pace of adenosine
triphosphate (ATP) catabolism,54 and where its extracellular level rapidly reaches
and exceeds the threshold necessary for stimulation of A3 receptors.
55–57 But, even
before that level is reached, enough adenosine is already present to activate the neu-
roprotective A1 receptors strategically located in the perisynaptic regions of neurons
(see Ref. 58 for the most recent review). An important aspect of this process is the
fact that enhancement of adenosine release is not a global, indiscriminate process but
rather a localized “adenosine pulse” that is both event and site specific event.59
While it has not been demonstrated due to the substantial technical difficulties in
measurement of its interstitial concentration,60 it may be expected that the level of
adenosine released into the extracellular space diminishes with the distance from the
center of the metabolic disturbance (FIG. 2). Thus, in focal ischemia, the territory of
FIGURE 2. Schematic representation of the ischemic focus and the penumbra zone. It
is very likely that the concentration of interstitial adenosine released during ischemia
([ADO]e) increases progressively in the direction of the ischemic focus, attaining its highest
value within the focus itself.
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the intensely hypoxic/ischemic tissue enveloping the immediate proximity of the oc-
cluded vessel will be rapidly surrounded by a zone of elevated extracellular adenos-
ine in which the concentration of the latter is high enough to sustain continuous
stimulation of A1 receptors. Since the main effects induced by such stimulation man-
ifest as the reduction of glutamate release, depression of N-methyl-D-aspartate (NM-
DA) receptor hyperstimulation, lowered influx of Ca2+, etc., the net result shows as
diminished electrical activity, reduced metabolic pace, and hypothermia (for re-
views, see Refs. 58 and 60–62). Consequently, the progression of the infarct enlarge-
ment may be slowed down and, in cases of very mild ischemia, arrested entirely.
There is, indeed, indirect evidence for such a possibility. Thus, studies of Matsumoto
et al.63 have shown that depression of the local cerebral blood flow (CBFL) to 25 ml/
100 g/min (i.e., above the level of bona-fide ischemia) is sufficient to raise adenosine
5–15-fold above its resting concentration, i.e., enough to activate A1 receptors. Ex-
tracellular concentration of glutamate, on the other hand, begins to increase when
CBFL decreases to 20 ml/100g/min. Since activation of A1 receptors results in hy-
perpolarization of the presynaptic terminals and attenuation of glutamate release, the
latter process will be operational at CBFL values that are depressed below normal
but are still above the level necessary to induce neuronal damage.64 There are thus
good reasons to believe that adenosine A1 receptors may be an important element
sustaining the existence of the “penumbra zone,”64 i.e., metabolically depressed but
still viable volume of cerebral tissue surrounding the infarct core. Eventually, since
the stimulation of A1 receptors effectively increases the threshold of critical NMDA
receptor input frequencies (i.e., depresses receptor excitability65), and since activity-
dependent release of adenosine is, in turn, directly related to the intensity of NMDA
and AMPA receptor stimulation,66–68 the local extracellular concentration of ade-
nosine will decrease due to the attenuation of glutamate receptor excitability, and
due to the rapid metabolic removal of extracellular adenosine. In consequence, and
providing the original insult is mild (e.g., occlusion of a minor arteriole), the tissue
within the penumbra zone will regain its normal (or almost normal) function. Anti-
inflammatory actions elicited by stimulation of A2A receptors (reviewed in Ref. 69)
will unquestionably assist in this process. Thus, but for the existence of A3 receptors,
the endogenous mechanism aimed at the reduction of neuronal injury would be an
ideal example of interaction among several receptor systems whose joint task is to
maintain functional integrity of the brain. However, many hitherto described effects
elicited by the stimulation of A3 receptors appear to contradict that goal entirely.
As discussed above, activation of A3 receptors results in the desensitization of A1
receptor-mediated inhibition of excitatory synaptic transmission.15 With the inhibi-
tory effect of A3 receptors on IIImetGluR, whose stimulation modulates glutamate
signaling,39 the net effect induced by the A3 receptors may be the enhancement of
glutamate release, invigoration of ischemic NMDA receptor activity, and actual am-
plification of the subsequent neurotoxic phenomena. Since enhanced activity of
NMDA/AMPA receptors increases concentration of interstitial adenosine, the pro-
cess of “egotropic inhibition” sustained by the interaction of A1 and NMDA recep-
tors transforms rapidly into a self-fueling “egotropic excitation,” in which the
continuously increasing production of adenosine caused by intraischemic catabo-
lismm of ATP activates A3 receptors. A3 receptors interact, in turn, with A1 and
IIImetGluRs and decrease their inhibitory impact on glutamate release. The constant
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presence of the latter sustains activation of NMDA and non-NMDA receptors con-
tributing to further release of adenosine, etc. The intensity of neurodestructive pro-
cesses initiated by the initial intraischemic “glutamate burst” increases rapidly and
sustains propagation of the neuronal destruction. Stimulation of A3 receptors with
micromolar concentration of their agonists results in apoptotic death of astro-
cytes.13,41 While it is unknown whether A3 receptors participate directly in the is-
chemia-evoked failure of glutamate uptake,70 it is plausible that the process of A3
receptor-induced apoptosis may be the source of such failure, contributing even fur-
ther to the continuous presence of extracellular glutamate. The fairly rapid process
of ischemia-induced apoptosis of astrocytes52,71 is, most likely, hastened by A3 re-
ceptor-mediated induction of NOS,14,45 since nitric oxide pathway has been impli-
cated in both glial and neuronal apoptosis.72–74 Thus, activation of adenosine A3
receptors by maximal intraischemic concentration of extracellular adenosine ap-
pears to trigger a massive destruction of cellular components within the entire vol-
ume of the tissue exposed to the most severe ischemia. This intensely “suicidal” role
of A3 receptors has been confirmed by the studies of global and focal ischemia,
where preischemic administration of the selective A3 receptor IB-MECA vastly am-
plified the subsequent brain damage43 (see FIG. 1). While such paradoxical function
of a receptor may have a remote evolutionary value in the context of removing from
the population its members handicapped by the intense brain damage incurred, for
example, during a mating fight, there are other, and unquestionably more efficient,
mechanisms to achieve this goal. More importantly, from the point of individual sur-
vival, the “killer” role of cerebral A3 receptor offers no biological advantage at all,
especially that in the other tissues (e.g., heart, see Refs. 29, 30) stimulation of A3
receptors is clearly protective. Very recent studies of von Lubitz et al. (this confer-
ence, and in preparation), in which administration of A3 receptor agonist (IB-
MECA) shortly after induction of permanent middle cerebral artery in mice resulted
in a highly significant reduction of the infarct size (FIG. 1), may offer some indica-
tions on the likely function of A3 receptors in the context of brain injury.
As indicated, it is very likely that the concentration of interstitial adenosine de-
creases with the distance from the ischemic core (FIG. 2). Hence, within the core it-
self, adenosine will reach a micromolar level adequate to fully stimulate A3
receptors, and resulting in the full range of their destructive effects (FIG. 3). Further
away, where the concentration decreases to high nanomolar values, more “benign”
effects of A3 receptors will predominate, i.e., activation and proliferation of
astrocytes13,41 (see also Ref. 52), antiinflammatory effects.24,32–34 Combining their
effects with the inhibitory and antiinflammatory effects mediated by A1 and A2 re-
ceptors, respectively, the A3 receptors will enhance the chances of survival of the tis-
sue within the volume that, most likely, constitutes the center of the penumbra zone.
Finally, at the periphery of the penumbra, the concentration of adenosine will be,
most likely, high enough to sustain prolonged activity of A1 and A2 but not A3 re-
ceptors, resulting in “prophylactic” effects, i.e., reduction of the intensity of
glutamatergic neurotransmission (and hence metabolism) by A1 and vasodilation by
A2A to assure adequate blood supply to the outer rim of penumbra. Viewed in such
light, adenosine A3 receptor becomes an “in situ surgeon” rather than a “killer:” met-
abolic and physical excision of the ischemic core is afforded by the isolation of the
affected volume from further blood supply through areteriolar vasoconstriction,21
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and through A3 receptor-mediated intensification of tissue damage (astrocytes and
neurons). Activation of astrocytes within the inner rim of the penumbra promotes
rapid scar development,52 while, at the same time, enhancing neuronal protection
through neurotrophin synthesis, potassium buffering, and neurotransmitter uptake50
within the rest of penumbra volume. Hence, the damage may be contained more eas-
ily, and the continuing survival with less than debilitating neurological deficit be-
comes more likely. Thus, the adenosine A3 receptor becomes an indispensable
component of the “graded injury response complex,” and finds a place in Newby’s75
concept of adenosine as a “retaliatory metabolite” that is as important as that of the
other two adenosine types—A1 and A2,
Much of the preceding discussion is speculative, and the evidence is missing, al-
though the emerging data point compellingly in the direction outlined above. The
overriding question of the A3 receptor biological role is still awaiting a plausible an-
swer. Likely, there may be several roles, their nature depending on the studied tissue,
and the context of function within the continuum of functions. But, indisputably, the
A3 receptor is more than just a variation on the “adenosine theme.”
FIGURE 3. Schematic representation of the possible interactions between adenosine
receptors and their effects during stroke/brain injury. In the focal volume, the actions of A3
receptors predominate, resulting in enhanced excitotoxic phenomena and diminished astro-
cytic efficacy. Within the penumbra, there is a gradual transition from A3 receptor-mediated
effects (close to the focus) to weak A3 receptor stimulation accompanied by the intense
stimulation of A1 receptors induced by endogenously released adenosine. As a result, at the
periphery of the penumbra, one may expect enhanced A1 receptor-mediated inhibition of
glutamate release, and lowered intensity of stimulation accompanied by astrocyte activation
resulting from activation of A3 receptors. In the unaffected volume of the brain, A1 receptor-
mediated effects predominate. See text for further discussion.
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